Century Therapeutics, Inc. (IPSC)
$0.00-$0.02 (-0.88%) TodayExtended Hours
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 5,286 | $12K |
| Grant or award | 5 | 370,000 | |
| Tax withholding / forfeiture | 4 | 45,842 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
49 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Douglas Carr - Officer | Grant or award | Common Stock | 110,000 | $0.00 | - | |
| Douglas Carr - Officer | Grant or award | Stock Option (right to buy) | 225,000 | $0.00 | - | |
| Brent Pfeiffenberger - Officer | Open-market purchase | Common Stock | 52,000 | $0.58 | $30K | |
| Chad Cowan - Officer | Open-market sale | Common Stock | 5,462 | $0.50 | $3K | |
| Brent Pfeiffenberger - Officer | Open-market purchase | Common Stock | 35,000 | $0.50 | $17K | |
| Brent Pfeiffenberger - Officer | Open-market sale | Common Stock | 32,456 | $0.45 | $15K | |
| Douglas Carr - Officer | Open-market sale | Common Stock | 292 | $0.59 | $171 | |
| Chad Cowan - Officer | Grant or award | Common Stock | 762,543 | $0.00 | - | |
| Douglas Carr - Officer | Open-market sale | Common Stock | 263 | $0.50 | $132 | |
| Gregory Russotti - Officer | Open-market sale | Common Stock | 539 | $0.50 | $270 | |
| Brent Pfeiffenberger - Officer | Open-market sale | Common Stock | 488 | $0.50 | $244 | |
| Brent Pfeiffenberger - Officer | Grant or award | Common Stock | 1,587,614 | $0.00 | - | |
| Douglas Carr - Officer | Open-market sale | Common Stock | 296 | $0.53 | $158 | |
| Cynthia M. Butitta - Director | Grant or award | Stock Option (right to buy) | 44,000 | $0.00 | - | |
 Joseph Jimenez - Director | Grant or award | Stock Option (right to buy) | 44,000 | $0.00 | - | |
| Brent Pfeiffenberger - Officer | Tax withholding / forfeiture | Common Stock | 243,447 | $1.44 | $351K | |
| Douglas Carr - Officer | Tax withholding / forfeiture | Common Stock | 16,611 | $1.26 | $21K | |
| Douglas Carr - Officer | Open-market sale | Common Stock | 283 | $1.23 | $347 | |
| Adrienne Farid - Officer | Open-market sale | Common Stock | 1,033 | $1.23 | $1K | |
| Morgan Conn - Officer | Grant or award | Common Stock | 60,148 | $0.00 | - | |
| Morgan Conn - Officer | Grant or award | Stock Option (right to buy) | 360,890 | $0.00 | - | |
| Chad Cowan - Officer | Grant or award | Common Stock | 74,376 | $0.00 | - | |
| Chad Cowan - Officer | Grant or award | Stock Option (right to buy) | 446,250 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 49 IPSC filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Century Therapeutics, Inc. (IPSC) had 14 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for IPSC runs to 49 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of IPSC were filed in the last 90 days. 2 purchases are on record for this company.
5 insider sales of IPSC were filed in the last 90 days, totaling $12K.
This page tracks IPSC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add IPSC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
